Navigation Links
Survival rates for pediatric bone marrow transplants top in nation

The UCSF Benioff Children's Hospital has the best overall survival rates in the nation for bone marrow transplants, according to a recent independent review of 156 programs nationwide.

The Pediatric Blood and Marrow Transplant Program, led by Morton Cowan, MD, was ranked number one for survival performance by the federally mandated review program of the Center for International Blood and Marrow Transplant Research (CIBMTR).

The 156 transplant centers were reviewed based on the number of transplants done annually, adjusted for risk, and estimated the chance for survival one year post transplant. Overall, the estimated chance of survival after one year was 63.4 percent. Of the 156 centers reviewed, only 14 (9 percent) were considered over performers, with the UCSF Pediatric Bone Marrow Transplant Program ranked number one with a survival rate of 87.6 percent.

Additionally, the Adult Hematology and Blood and Marrow Transplant (BMT) at UCSF Medical Center was again named an "over performer" by the CIBMTR. This is the second consecutive year the service has been recognized as an over performer. The adult program is also one of 14 nationwide recognized for exceeding U.S. expectations in patient survival rates for those undergoing a blood or marrow transplant from either a relative or an unrelated donor. At UCSF, 75 percent of adult patients receiving a BMT survive at least a year, compared to the national average of 63.4 percent.

Christopher Dvorak, MD, a pediatric blood and bone marrow transplant specialist at the UCSF Benioff Children's Hospital, wasn't surprised by the results knowing firsthand the level of commitment to success that exists within and well beyond the pediatric BMT team.

"We work incredibly hard and have an attention to detail and dedication to our policies attempting to limit transplant-associated mortality," said Dvorak, who is also head of the national Pediatric Blood and Marrow Transplant Consortium's Supportive Care Strategy Sroup.

The UCSF pediatric BMT program has expanded in recent years by adding two physicians and two nurse practitioners, ultimately increasing the number of transplants performed. UCSF's interdisciplinary collaboration among health care professionals also adds a nuanced level of support. "Some of the credit for our success must go to the pediatric intensive care unit which helps patients survive when then get critically ill," Dvorak said.

The pediatric BMT unit also gives more individualized attention to the dosing of chemotherapy medications through increased interactions with the UCSF School of Pharmacy. "We have a great School of Pharmacy and now have a doctor of pharmacy on our team, helping us with tailoring the chemo regimens. We have great nurses and nurse practitioners through the School of Nursing as well, and all of that plays into our success."

While adult bone marrow transplants are usually performed to treat blood-related cancers, pediatric transplants are necessary for a host of other reasons. Immunodeficiency syndromes, defects in red blood cells, inborn errors of metabolism, and several types of cancer account for many of the BMT transplants performed in children at UCSF.

Contact: Juliana Bunim
University of California - San Francisco

Related medicine news :

1. Gene Mutations May Boost Ovarian Cancer Survival: Study
2. Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years
3. Study showed oxaliplatin improved colon cancer patient survival
4. Drug improves survival of colorectal cancer patients, trial results show
5. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
6. Personalized gene therapies may increase survival in brain cancer patients
7. Race, Gender, Dementia May Affect Parkinsons Survival
8. Demographic and clinical factors appear associated with survival in patients with Parkinsons disease
9. Ovarian cancer study proves drug delays disease progression, may improve survival
10. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
11. Researchers identify potential target to delay metastatic pancreatic cancer and prolong survival
Post Your Comments:
Related Image:
Survival rates for pediatric bone marrow transplants top in nation
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: